US 2018/0000914 A1 · ANTI-HSP70 SPECIFIC CHIMERIC ANTIGEN RECEPTORS (CARS) FOR CANCER IMMUNOTHERAPY

Abstract

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from an anti-HSP70 monoclonal antibody, conferring specific immunity against HSP70 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating in particular leukemia.

Claims72

Dependent claims

A heat shock protein 70 (hHSP70) specific chimeric antigen receptor (CAR) comprising at least:

an extra cellular ligand binding-domain specific for hHSP70,
a transmembrane domain, and
a cytoplasmic signaling domain,

Dependencies are inferred from the claim text.

Facts

Application

15/546,604Filed 25 Jan 2016

Priority

DK PA20157004426 Jan 2015

Published

4 Jan 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification40 codes

C07K 16/2866
Against receptors, cell surface antigens or cell surface determinants: against receptors for cytokines, lymphokines, interferons
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]

Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy

Life of this patent

Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy

Life of this patent

Abstract

Claims72